Literature DB >> 11098484

UFT: mechanism of drug action.

C H Köhne1, G J Peters.   

Abstract

The mechanism of action of fluorouracil (5-FU) and the oral fluoropyrimidines and the importance of biochemical modulation and inhibition of dihydropyrimidine dehydrogenase for oral application of the prodrugs of 5-FU are discussed. The regulation of thymidylate synthase, as well as its roles as a target for antineoplastic activity and in drug resistance, are also mentioned. The more downstream events of 5-FU action and their implication in 5-FU resistance, with the possible involvement of the Fas/FasL system and the proteins associated with apoptosis regulation, are highlighted. Also discussed is the suggestion that the oral 5-FU prodrug tegafur and uracil (UFT) and its metabolites function as an angiogenesis inhibitor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11098484

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  9 in total

Review 1.  Current and Future Therapies for Pancreatic Ductal Adenocarcinoma.

Authors:  Áine Sally; Ryan McGowan; Karen Finn; Brian Michael Moran
Journal:  Cancers (Basel)       Date:  2022-05-13       Impact factor: 6.575

2.  Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.

Authors:  Kotaro Miyake; Satoru Imura; Tomoharu Yoshizumi; Tetsuya Ikemoto; Yuji Morine; Mitsuo Shimada
Journal:  Int J Clin Oncol       Date:  2007-04-27       Impact factor: 3.402

3.  TEGAFIRI is an effective alternative regimen for the management of recurrent or metastatic colorectal cancer.

Authors:  Tzu-Chi Hsu
Journal:  Oncol Lett       Date:  2015-01-07       Impact factor: 2.967

4.  Maintenance tegafur-plus-uracil after adjuvant concurrent chemoradiotherapy may improve outcome for resected oral cavity squamous cell carcinoma with extranodal extension.

Authors:  Pei-Wei Huang; Chien-Yu Lin; Li-Yu Lee; Chia-Hsun Hsieh; Cheng-Lung Hsu; Chi-Ting Liau; Kang-Hsing Fan; Shiang-Fu Huang; Chun-Ta Liao; Tung-Chieh Chang; Hung-Ming Wang
Journal:  Front Oncol       Date:  2022-09-28       Impact factor: 5.738

Review 5.  Emerging treatment options for nasopharyngeal carcinoma.

Authors:  Lu Zhang; Qiu-Yan Chen; Huai Liu; Lin-Quan Tang; Hai-Qiang Mai
Journal:  Drug Des Devel Ther       Date:  2013-02-01       Impact factor: 4.162

6.  Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.

Authors:  W Ichikawa; H Uetake; Y Shirota; H Yamada; T Takahashi; Z Nihei; K Sugihara; Y Sasaki; R Hirayama
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

7.  Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients.

Authors:  Usman Arshad; Su-Arpa Ploylearmsaeng; Alexander Jetter; Max Taubert; Mats O Karlsson; Oxana Doroshyenko; Dorothee Langer; Edgar Schömig; Sabine Kunze; Semih A Güner; Roman Skripnichenko; Sami Ullah; Ulrich Jaehde; Uwe Fuhr
Journal:  Cancer Chemother Pharmacol       Date:  2020-03-09       Impact factor: 3.333

8.  Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial.

Authors:  Raghav Sundar; Nesaretnam Barr Kumarakulasinghe; Yiong Huak Chan; Kazuhiro Yoshida; Takaki Yoshikawa; Yohei Miyagi; Yasushi Rino; Munetaka Masuda; Jia Guan; Junichi Sakamoto; Shiro Tanaka; Angie Lay-Keng Tan; Michal Marek Hoppe; Anand D Jeyasekharan; Cedric Chuan Young Ng; Mark De Simone; Heike I Grabsch; Jeeyun Lee; Takashi Oshima; Akira Tsuburaya; Patrick Tan
Journal:  Gut       Date:  2021-05-12       Impact factor: 23.059

9.  Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity.

Authors:  M de Bruin; T van Capel; K Van der Born; F A Kruyt; M Fukushima; K Hoekman; H M Pinedo; G J Peters
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.